European Commission Proposes Rules Changes To Create Unitary Patent Court 29/07/2013 by Intellectual Property Watch 3 Comments The final legislative piece needed for the establishment of a unitary EU patent system emerged from the European Commission today.
United States Confounded By Standard-Essential Patents 29/07/2013 by Steven Seidenberg for Intellectual Property Watch 2 Comments The United States is in a muddle over standard-essential patents. The nation’s courts and its executive agencies all agree that these patents play vital roles in the economy, but they disagree about what remedies are available when these patents are infringed. A recent decision by the US International Trade Commission has added to the confusion.
Push For “March-In Rights” To Prevent Myriad From Asserting Patents On Cancer Test 22/07/2013 by Brittany Ngo for Intellectual Property Watch 1 Comment Despite last month’s United States Supreme Court decision on a case involving Myriad Genetics, which struck down some of Myriad’s patents related to human genes, Myriad has filed infringement suits against two companies that had announced they would begin offering lower-cost tests for the breast cancer genes in question.
Public Interest Groups Ask US Court To Invalidate Stem Cell Patent 03/07/2013 by Intellectual Property Watch Leave a Comment A human embryonic stem cell patent held by the Wisconsin Alumni Research Foundation (WARF) should be invalidated, according to a legal filing made on 2 July by two public interest groups.
MSF: Prices On Latest ARV Drugs Under Patent Too High 02/07/2013 by Intellectual Property Watch Leave a Comment The price of first- and second-line anti-retrovirals (ARVs) have declined due to increased generic competition, while third-line regimens remain “exorbitantly priced,” according to the latest edition of a publication from Médecins Sans Frontières (MSF).
Medicines Patent Pool Signs New Licence Agreements 26/06/2013 by Intellectual Property Watch 1 Comment The Medicines Patent Pool, Shilpa Medicare, and Gilead Sciences have signed an agreement to increase access to HIV treatment medicines. The agreement will allow Shilpa Medicare to manufacture “five key HIV medicines for sale in 100-112 countries,” and the goal is to cover “a majority of people living with HIV.”
US Supreme Court Restricts Gene Patents … A Little 17/06/2013 by Steven Seidenberg for Intellectual Property Watch 2 Comments Last Thursday, the United States Supreme Court overturned more than 30 years of precedents and ruled that isolated genes cannot be patented. They are products of nature and thus not patent-eligible subject matter, the court unanimously held in Assoc. for Molecular Pathology v. Myriad Genetics, Inc. This ruling puts the US at odds with most other nations, which allow genes to be patented. But because other major nations grant narrower gene patents, the net effect of Myriad will be to shift the US position on gene patents closer to that of other nations.
Myriad Case Decided: Natural Human Genes Not Patentable In US 14/06/2013 by Intellectual Property Watch 3 Comments The United States Supreme Court came to a decision yesterday on the case of Association for Molecular Pathology v. Myriad Genetics, Inc., striking down Myriad’s patent on isolating human genes from the bloodstream.
IP5 Discuss Patent Harmonisation 06/06/2013 by Intellectual Property Watch 1 Comment Officials from the IP5, the five largest intellectual property offices in the world, met this week to move forward on harmonising patent law procedure between the offices.
White House Takes Major Action Against “Patent Trolls” 04/06/2013 by William New, Intellectual Property Watch 4 Comments The White House today announced “major steps to improve innovation in high tech patents” by restricting activities of “patent assertion entities,” also known as “patent trolls.” The list included five executive actions and seven legislative recommendations.